Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer ...
Discover the latest articles and news in related subjects. Children’s respiratory clinic visit data were obtained from the database of Taiwan’s National Health Insurance program, which is contracted ...
Partnerships between industry and academia have allowed for better targeted and more cost effective approaches to drug discovery. Thanks to this close collaboration, academic institutes worldwide have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results